WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Stem Cell Stevie
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Industrial Impact
PRNewswire | June 14, 2023
PhenomeX Inc. the functional cell biology company, announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate. The study, conducted by researchers from the La J...
Medical
Nordic Bioscience | June 17, 2022
Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up. Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.<...
Medical, Industry Outlook
Globenewswire | August 16, 2023
Graf Acquisition Corp. IV and NKGen Biotech, Inc. on August 14, 2023 announced that Graf’s registration statement on Form S-4 relating to the previously announced business combination (the “Business Combination”) with NKGen, has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”). Graf also commenced mailing the definitive proxy statement/prospectus on August 14, 2023, which was included in the Registration Statement, relating to...
Lilly | January 28, 2021
Eli Lilly and Company, Vir Biotechnology, Inc. also, GlaxoSmithKline plc declares a collaboration effort to assess a mix of two COVID-19 therapies in low-risk patients with mild to direct COVID-19. Lilly has extended its progressing BLAZE-4 trial to assess the organization of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (otherwise called GSK4182136) 500mg, two killing antibodies that quandary to various epitopes of the SARS-CoV-2 spike protein. This unique collaboration effort denotes the first ...
Article
infographic
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE